Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...

The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...

Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug ...

The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, automation, and data science that drives innovation in drug development. Eikon ...